Regeneron registers Phase 1b trial of Factor XI/XII antibodies in dialysis patients

Regeneron posted one new trial registration this week covering three investigational antibodies aimed at a hard-to-treat dialysis population.

• Regeneron registered a Phase 1b study (NCT07759167, not yet recruiting) testing three monoclonal antibodies, REGN9933 (also known as amrecibart), REGN7508 (also known as cenvacibart), and REGN9533, in adults with End-Stage Kidney Disease treated with hemodialysis and standard anticoagulant treatment such as heparin to reduce clotting risk¹. The study plans to enroll 36 participants¹ and will primarily track side effects that may occur from taking REGN9933, REGN7508, or REGN9533¹, with an estimated start date of September 9, 2026.